Universe Pharmaceuticals INC (NasdaqCM: UPC)
Health Care · Pharmaceuticals · CN
$5.36
-5.13% today · +65.3% 1Y
Universe Pharmaceuticals INC (NasdaqCM: UPC) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $3.68M and employs 216 people.
Over the last twelve months the share price has gained 65.3%, trading between 2.00 and 17.96.
Tweenvest scores Universe Pharmaceuticals INC across four factors: quality 59/100, value 53/100, growth 0/100. Its strongest factor is quality.
UPC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.68M
- Revenue (TTM)
- $17.74M
- P/E
- —
- EPS
- -3.45
- Dividend yield
- —
- Beta (5Y)
- 1.53
- 52-week high
- $17.96
- 52-week low
- $2.00
- Avg volume (3M)
- —
- Shares outstanding
- 651.30K
- Employees
- 216
- Next earnings
- —
About Universe Pharmaceuticals INC
Universe Pharmaceuticals Inc. (UPC) operates as a pharmaceutical enterprise primarily focused on the Chinese market. The company specializes in the production, promotion, and sale of products derived from traditional Chinese medicine (TCM). These remedies are designed to address common chronic health issues prevalent among the elderly, promoting physical well-being and longevity, in addition to offering medications for cold and flu symptoms. Beyond its own manufactured goods, UPC also functions as a distributor and vendor for a diverse range of third-party products. This extensive portfolio includes biomedical drugs, medical instruments, traditional Chinese medicine 'pieces' (raw ingredients), and various dietary supplements. Its clientele spans across the healthcare sector, encompassing other pharmaceutical companies, hospitals, clinics, and major drugstore chains. Established in 2019, the company's operations are headquartered in Ji'An, China, and it functions as a subsidiary of Sununion Holding Group Limited.
- ISIN
- KYG9442G1385
- Founded
- 1998
- Listed since
- Mar 23, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,246.93 | -0.67% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.04 | +1.04% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $150.66 | -1.24% |
| Roche Holding AGSWX: ROP | $368.80B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $27.97 | -0.36% |
Figures last refreshed Aug 18, 2026.